Updated software provides clinical guidance on two new COVID-19 drugs shown to reduce time spent in ICU, grows Think’s COVID-19 content library to total of 40 clinical order sets

Toronto, March 11, 2021 — Think Research Corporation (TSXV: THNK) or (the “Company” or “Think Research“), a company focused on transforming healthcare through integrated digital health software solutions, announced today the release of two new COVID-19 decision support tools to guide prescribing of the latest drug therapies for critically ill hospitalized COVID-19 patients.

The latest updates include two immunosuppressive drugs shown to impact patient survival rates and help reduce the amount of time spent in the ICU by up to 10 days. Think’s COVID-19 order sets are cloud-based digital checklists that distill and digitize clinical research to improve patient outcomes, avoid medical errors and reduce waste in healthcare spending. 

The company has now developed 40 COVID-19 decision support tools for varying patient needs. Think’s clinical knowledge software is currently deployed in more than 250 hospitals globally.

Think Research CEO Sachin Aggarwal said “The COVID-19 pandemic is ongoing and continuing to cost thousands of lives every day. The volume of constantly evolving information and best practices for fighting this disease is almost incomprehensible. It can be very difficult for frontline clinicians to manage all of the changing evidence, so our software brings it right to their fingertips.”  

Think Research Senior Vice President of Clinical R&D Kirsten Lewis said “When the pandemic first hit, we began making COVID-19 support tools, including screening tools and order sets. While COVID-19 vaccines are incredibly important in combating this disease and ending the pandemic, we wanted to ease the burden for care providers in hospitals, incorporating evolving best practices and treatment options for those with COVID-19 in order to improve outcomes.” 

The new order sets include two immunosuppressive drugs used to treat rheumatoid arthritis, tocilizumab and sarilumab, shown to impact COVID-19 patient survival rates and cut the time spent in the ICU by up to 10 days. In severe COVID-19 patients, tocilizumab is also shown to reduce the need for mechanical ventilation, decrease the risk of death and increase the chance of a successful hospital discharge.

Think Research order sets allow doctors and nurse practitioners to make patient-centred decisions based on the latest evidence-based health knowledge. Think currently has developed 1,000 order sets for various conditions, including heart failure and COPD. 

For more information: https://www.thinkresearch.com/ca/investors/

Contact: Genevieve Tomney, VP, Communications, Think Research, Direct: 416.460.5784, genevieve.tomney@thinkresearch.com

About Think Research Corporation

Think Research is an industry leader in delivering knowledge-based digital healthcare solutions. The Company’s focused mission is to organize the world’s health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think Research’s cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors care. Think Research is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans five continents and more than 2,800 healthcare facilities.